Docoh
Loading...

OTLC Oncotelic Therapeutics

Mateon Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development investigational drugs for the treatment of orphan oncology indications. Its product pipeline includes CA4P and OXi4503. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

Company profile

Ticker
OTLC
Exchange
Website
CEO
Vuong Trieu
Employees
Incorporated
Location
Fiscal year end
Former names
MATEON THERAPEUTICS INC, OXIGENE INC
SEC CIK
IRS number
133679168

OTLC stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

24 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 850.72K 850.72K 850.72K 850.72K 850.72K 850.72K
Cash burn (monthly) (positive/no burn) (positive/no burn) 679.29K 581.03K 417.17K 341.25K
Cash used (since last report) n/a n/a 2.78M 2.37M 1.7M 1.39M
Cash remaining n/a n/a -1.93M -1.52M -853.95K -543.72K
Runway (months of cash) n/a n/a -2.8 -2.6 -2.0 -1.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Jul 21 David Diamond Stock Options Common Stock Grant Aquire A No No 0.1626 451,467 73.41K 451,467
8 Jul 21 Amit B. Shah Common Stock Grant Aquire A No No 0 298,837 0 358,837
8 Jul 21 Amit B. Shah Stock Options Common Stock Grant Aquire A No No 0.1626 698,256 113.54K 698,256
8 Jul 21 Saran Saund Common Stock Grant Aquire A No No 0 102,519 0 16,457,480
8 Jul 21 Saran Saund Stock Options Common Stock Grant Aquire A No No 0.1626 216,279 35.17K 216,279
8 Jul 21 King Steven W Stock Options Common Stock Grant Aquire A No No 0.1626 357,412 58.12K 357,412
8 Jul 21 Maida Anthony E Iii Stock Options Common Stock Grant Aquire A No No 0.1626 400,000 65.04K 400,000
31 Mar 21 Saran Saund Common Stock Conversion Aquire C No No 0 16,354,961 0 16,354,961
31 Mar 21 Saran Saund Series A Convertible Preferred Stock Common Stock Conversion Dispose C No No 0 16,355 0 0
31 Mar 21 King Steven W Common Stock Conversion Aquire C Yes No 0 3,291,720 0 3,330,647

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • A comparison of the Company’s operating results for the year ended December 31, 2019 and 2018, respectively, is as follows.
  • We recorded a net loss of approximately $10.0 million for the year ended December 31, 2020, compared to a net loss of approximately $6.6 million for the same period in 2019. The increased loss of approximately $3.3 million for the year ended December 31, 2020 as compared to the same period of 2019 was primarily due to approximately $5.0 million of higher operational expenses related to the Company, $1.2 million primarily related to interest expense, including amortization of normal and accelerated debt costs related to the debt raised by the company in 2019 and 2020, a loss of $0.3 million of loss on non-cash conversion of debt and recording a higher non-cash loss on conversion of value of derivatives of $0.2 million; partially offset by the recording revenue of approximately $1.7 million and lower write off of long term investment of $1.7 million that we incurred during 2019. The financial information presented includes very nominal expenses for PointR operations for the year ended December 31, 2019.
  • We recorded services revenue of $1.7 million during the year ended December 31, 2020 as compared to no revenues during the same period ended in 2019. The services revenue of $1.2 million was recorded from services provided to GMP in connection with the development of OT-101 for COVID-19 and included reimbursement of costs incurred of approximately $41 thousand. We also recorded $0.5 million of revenues from ATB upon the successful completion of the in-vivo efficacy studies based on the ATB Agreement.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accuracy, accurately, Arizona, ArtiHealth, ARTIVeda, ARTIVedaTM, asymptomatic, award, Ayurvedic, BCF, begun, bid, Bloomberg, BMS, called, Charter, classification, commensurate, conservative, constituting, Correspondingly, CRO, currency, custodian, Daily, discontinuation, dollar, duration, electronic, employed, enforced, EUA, exact, experience, exposure, external, facility, factor, faster, feel, Fisher, Flipkart, foreign, forfeited, forfeiture, forgivable, group, indefinitely, insolvency, invoiced, issuer, launch, launched, length, lesser, light, lived, Log, longer, MATN, maximize, median, mitigated, mortgage, OTLC, overestimate, Overview, pattern, payroll, policy, powered, preceding, preclinical, preserve, proceeding, pronounced, prospectively, published, PulmoHeal, pulmohealtm, Pvt, recovery, reduced, renowned, rent, repay, reputable, resale, rest, RR, Salcit, screening, sensitivity, showed, showing, sicklier, size, SOC, spin, Squibb, survey, therapy, topline, trend, twenty, ultimately, uncollateralized, underestimate, undertaken, unforgiven, vide, voluntary
Removed: acquirer, Adhera, allocating, anniversary, arrangement, assumed, attributable, Bank, bore, carry, categorical, close, Codification, compensate, compensatory, computer, Confidential, demand, developer, discretionary, document, duly, evaluated, Exhibit, fact, factual, focused, found, historic, inaccurate, incorporated, incorrect, licensing, lieu, materiality, merged, migrated, negotiation, occurred, orphan, owed, percentage, practicable, pre, prepaid, publicly, read, recapitalization, recent, recently, Reclassification, Redacted, relied, remember, replace, return, reverse, reviewing, salary, satisfaction, separately, Silicon, smaller, surviving, thereunto, undersigned, unexpected, unrealized, Valley, viewed, website, write